Compare ASB & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ASB | DNTH |
|---|---|---|
| Founded | 1861 | 2015 |
| Country | United States | United States |
| Employees | 4000 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.6B |
| IPO Year | N/A | 2018 |
| Metric | ASB | DNTH |
|---|---|---|
| Price | $27.77 | $90.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 13 |
| Target Price | $29.75 | ★ $121.00 |
| AVG Volume (30 Days) | ★ 1.5M | 425.6K |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,036,000.00 |
| Revenue This Year | $21.24 | N/A |
| Revenue Next Year | $8.86 | $29.48 |
| P/E Ratio | $10.23 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $22.48 | $16.77 |
| 52 Week High | $29.52 | $96.50 |
| Indicator | ASB | DNTH |
|---|---|---|
| Relative Strength Index (RSI) | 50.25 | 59.23 |
| Support Level | $27.15 | $81.16 |
| Resistance Level | $28.02 | $96.50 |
| Average True Range (ATR) | 0.54 | 4.45 |
| MACD | -0.04 | 0.25 |
| Stochastic Oscillator | 42.90 | 85.05 |
Associated Banc-Corp is a bank holding company based in the United States of America. The company, through its subsidiaries, provides a broad array of banking and non-banking products and services to individuals and businesses. The group operates in three reportable segments: Corporate and Commercial Specialty; Community, Consumer, and Business; and Risk Management and Shared Services. The majority of its revenue is derived from the Corporate and Commercial Specialty segment, which serves a wide range of customers, including larger businesses, developers, not-for-profits, municipalities, and financial institutions by providing lending and deposit solutions as well as support to deliver, fund, and manage such banking solutions.
Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.